tbuckley/cabot-search huggingface dataset:
Abstract 13613: Incidence of Heart Failure Among Black versus White Patients With Human Immunodeficiency Virus Infection in the United States, 2011-2017
Authors: Andreas P Kalogeropoulos, Kerry Cao, Jesse Kane, Aikaterini Papamanoli, Robin Jacob, Michelle E Bloom, Hal Skopicki
Journal: Circulation (2021)

Introduction: Black patients suffer higher rates of human immunodeficiency virus (HIV) and heart failure (HF) than any other race. In patients with HIV, rates of HF have declined, but disparities in incident HF may persist. To explore these disparities, we evaluated incidence of HF in Black and White patients with HIV. Methods: Using data from the TriNetX electronic health records network, we identified 93,322 adults (age 18+) patients from 47 centers in the United States with an HIV infection diagnosis (ICD-10 code B20) between 2011 and 2017 (to allow for ≥3-year follow up), without any previous record of HF diagnosis (ICD-10 code I50). We compared the incidence of HF (new ICD-10 code I50), HFrEF (codes I50.2 or I50.4), and HFpEF (codes I50.1 or I50.3) over a 3-year follow up in propensity-matched subsets of White and Black patients. We matched for demographics and clinically relevant background history, including antiviral medications. We used Kaplan-Meier (K-M) estimates and Cox models to compare incidence. Results: The baseline characteristics of the matched cohorts (27,388 Black and 27,388 White) were well balanced (with standardized mean differences ≤0.02 for all clinical characteristics), Table 1 . Within 3 years, there were 302 new cases of HF in Black and 220 in White patients. The corresponding 3-year K-M incidence of HF was 1.4% vs 1.0% (HR 1.34; 95%CI 1.12-1.59; P=0.001). The rates of presumable HFrEF (120 cases in Black vs 74 in White) were 0.55% vs 0.36% (HR 1.58; 95%CI 1.18-2.11; P=0.002) and those of presumable HFpEF (83 vs 65 cases) were 0.38% vs 0.31% (HR 1.24; 95%CI 0.90-1.72; P=0.19), respectively. Mortality at 3 years did not differ between Black (n=863; 3.8%) vs White (n=850; 3.8%) patients (HR 0.99; 95%CI 0.90-1.09; P=0.85). Conclusions: In matched cohorts of HIV patients, the 3-year incidence of HF was higher in Black vs White patients. These findings demonstrate racial disparities in HIV and HF, highlighting an intersection of diseases that warrants further study.
Abstract 13985: Targeting the Activin Receptor Type IIA for Therapeutics in Atrial Fibrillation
Authors: Claire Castro, Andy Yu, Ryan Hobson, Aneesh Bapat, Ashish Yeri, Se-Jin Lee, Patrick T Ellinor, Anthony Rosenzweig, Jason D Roh
Journal: Circulation (2021)

Introduction: Atrial fibrillation (AF) is the most common cardiac arrhythmia and a leading cause of stroke and heart failure. However, limited treatment options are available. The adipo-fibrokine Activin-A has been associated with AF in humans, and genome-wide association studies have implicated the Activin receptor type IIA (ActRIIA) in AF. Hypothesis: Our aim was to investigate the potential functional role of ActRIIA in AF pathophysiology. Methods: We used an Activin-A overexpression murine model (AOE) to determine if Activin-A/ActRII signaling increases AF inducibility and explored potential mechanisms by performing RNA sequencing. Comparative studies between the Activin-A binding receptors, ActRIIA and ActRIIB, were then conducted in vitro using siRNA knockdown (KD) in isolated cardiomyocytes and in vivo using cardiac specific ActRIIA or ActRIIB mouse knockouts (KO) in a high fat diet (HFD)-induced model of AF. Results: AOE mice displayed increased cardiac ActRII signaling, including increased FSTL3 mRNA expression (3.4-fold; p=0.005) and SMAD3 phosphorylation (2.7-fold; p=0.005). AF inducibility was markedly increased in AOE mice (75% versus 0% in controls), and was associated with decreased atrial conduction velocity (RA: 0.46±0.07 vs 0.61±0.09 m/s, p=0.005; LA: 0.54±0.18 vs 0.73±0.14 m/s, p=0.06). Pathway analysis of the cardiac transcriptome in AOE mice identified gap junctions as one of the most downregulated pathways (normalized enrichment score -2.8, FDR&lt;0.001) with 50% decreased expression of the AF-associated connexin, CX43 (p adj =1.2x10 -9 ). Conversely, ActRIIA KD increased CX43 expression in cardiomyocytes (mRNA: 2-fold; p=0.005; protein: 1.8-fold; p=0.07), which was not observed with ActRIIB KD (mRNA: 1-fold; p=0.9; protein: 0.9-fold; p=0.3). ActRIIA KO mice also displayed lower AF inducibility rates (67%) to HFD, compared to ActRIIB KO mice (80%) and controls (αMHCcre 83%, ActRIIA flox/flox 89%, ActRIIB flox/flox 100%). Conclusions: Activin-A/ActRII signaling increases AF inducibility in part by decreasing cardiomyocyte CX43 expression and atrial conduction. This effect is specifically mediated through the ActRIIA, not ActRIIB, suggesting Activin receptor specificity in AF pathophysiology.
A dual-gelling poly(N-isopropylacrylamide)-based ink and thermoreversible poloxamer support bath for high-resolution bioprinting
Authors: Adam M. Navara, Yu Seon Kim, Yilan Xu, Christopher L. Crafton, Mani Diba, Jason L. Guo, Antonios G. Mikos
Journal: Bioactive Materials (2021)

Extrusion bioprinting is a popular method for fabricating tissue engineering scaffolds because of its potential to rapidly produce complex, bioactive or cell-laden scaffolds. However, due to the relatively high viscosity required to maintain shape fidelity during printing, many extrusion-based inks lack the ability to achieve precise structures at scales lower than hundreds of micrometers. In this work, we present a novel poly(
Abstract 13238: Clinical Utility Of Hs-Tni In Healthy Thai Subjects With Intermediate Cardiovascular Risk
Authors: Piyachat Pipatpongsopon, Prin Vathesatogkit, Somlak Vanavanan, Anchalee Chittamma
Journal: Circulation (2021)

Introduction: In European countries, hs-cTnI is approved for risk stratification in general population. Whether this indication can be applied to Thai population is unknown. We test the utility of hs-cTnI as a risk stratification tool for incident cardiovascular disease among Thai subjects with intermediate cardiovascular (CV) risk and without previous cardiovascular disease. Hypothesis: Hs-cTnI can be used as a risk stratification tool in Thai subject who has intermediate cardiovascular risk. Methods: Data were retrieved from 1,757 subjects who had intermediate CV risk (7.5%-19.9%) and had no known CV disease from the electricity generating authority of Thailand (EGAT) study during the year 2007-2009. High-sensitive Troponin I was tested using the Abbot ARCHITECT i2000 SR system. Hs-cTnI was categorized into low, intermediate and high risk using gendered-specific cut-offs points. Major adverse cardiac event (MACE), defined as a composite of CV death, non-fatal myocardial infarction and non-fatal stroke, was collected and confirmed by medical record until 2017-2019. Survival analysis and net reclassification index (NRI) analysis were performed. Results: A total of 1,757 subjects had complete data for analysis. Mean age was 57-year-old, 77% were male. After 10 years, 88 CV event (5%) occurred. Median hs-cTnI was 3 (2.2, 4.1) mg/dL. The event rate was significantly highest in high-risk group of hs-cTnI (14%), followed by intermediate (6.4%) and low risk group (4.3%). Multivariate analysis adjusted for conventional risk factor from Thai CV risk score showed that hs-cTnI is an independent risk factor for MACE (HR 1.02, 95% CI 1.01 to 1.03). For the high-risk group, compared to low risk group, hazard ratio was 3.24, 95% CI 1.73 to 6.07 (p value for trend &lt; 0.001). The addition of hsTnI information to prognostic model yielded an NRI of 0.11 (p-value 0.006). Conclusions: In this intermediate CV risk population, elevation of hs-cTnI is not uncommon. Hs-cTnI is an independent risk factor for cardiovascular death, myocardial infarction and stroke. Hs-cTnI significantly improves the reclassification as shown by NRI. Hs-cTnI can be used as a risk stratification tool in Thai subject who has intermediate cardiovascular risk.
Abstract 12823: Efficacy, Optimal Duration and Safety of Adjunctive Cilostazol in Acute ST-elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention With Drug-Eluting Stents; a Multicenter, Randomized, Open Label, Phase 4 Trial
Authors: Soohyung Park, Byoung Geol Choi, Se Yeon Choi, Jae Kyeong Byun, Jinah Cha, Kyuho Lee, Seungmin Back, Jieun Lee, Dong Kang, Ji Bak Kim, Jah Choi, Seung-young Roh, Jin O Na, Cheol Ung Choi, Eung Ju Kim, Chang Gyu Park, Hong-Seog Seo, Seung Woon W Rha
Journal: Circulation (2021)

Background: Previous studies showed that the triple antiplatelet therapy (TAT) which is an addition of cilostazol on the top of conventional dual antiplatelet therapy (DAT, aspirin + clopidogrel) was associated with better clinical outcomes in ST-elevation MI (STEMI) patients as compared with DAPT but the optimal duration of TAT was not determined yet. Method: A total 985 patients underwent primary percutaneous coronary intervention (PCI) with drug-eluting stents (DES) were prospectively enrolled in 14 medical centers in Korea. We randomly assigned patients into 3 groups of DAT (aspiring and clopidogrel) for 12 months, TAT (aspirin, clopidogrel and cilostazol) for 1month or 6months. The primary end point was 1-year major adverse cardiovascular events (MACE), defined as the composite of all-cause death, non-fatal myocardial infarction (MI), stroke or repeat revascularization. The secondary endpoints were the incidence of cardiac death, stent thrombosis, bleeding events and each component of primary end point. Results: The primary end point was not different among the 3 groups (8.4% in the DAT, 11.0% in the TAT for 1month, 11.3% in the TAT for 6 months, p=0.427). However, incidence of cardiac death was significantly higher in TAT groups (0.3% vs 2.5% vs 1.3%, respectively, p=0.047). Regarding in-hospital outcomes, higher bleeding events occurred in TAT groups than DAT group (0.3% vs 3.2% vs 1.9%, p=0.027) without significant difference in major bleeding. Conclusion: TAT strategy with cilostazol on the top of DAT did not associated with reduced incidence of 1-year MACE as compared with DAT but may be associated with increased cardiovascular death and bleeding risk. Whether routine additional use of cilostazol for STEMI patients would be beneficial need further studies with larger study population.
제5차 대한간학회 춘계학술대회 초록집 : 알코올성 간경변 환자에서 C형 간염바이러스 감염의 빈도와 의의
Authors: 권소영 ( Kwon So Yeong ), 안명수 ( An Myeong Su )
Journal: Clinical and Molecular Hepatology (1999)
Abstract 9960: Soluble Low Density Lipoprotein Receptor-related Protein-1 Levels As A Potential Biomarker In Covid19
Authors: Mehmet Agirbasli, RABIA KORKMAZ, ferruh K isman
Journal: Circulation (2021)

Introduction: Low density lipoprotein receptor-related protein 1 (LRP1), is a multifunctional receptor. Soluble form (sLRP1) is measurable as a novel biomarker of inflammation and atherosclerosis. We hypothesize that sLRP1 levels can be associated with Covid19 disease onset and severity. Methods: We measured sLRP1 levels in 180 PCR positive, Covid19 patients admitted to the hospital (mean age 60± 19, M/F = 51/49). Controls (n=61) were selected from outpatients without significant comobidities. Results: Covid19 patients display significantly lower sLRP1 levels compared to the controls (p&lt;0.001). Covid19 patients are stratified based on the severity of Covid19 such as emergency room (n=44), inpatient service (n=95) and intensive care (n=41). Median sLRP1 levels are 2.27, 1.26, 1.36, and 1.73 μg/ml for controls, emergency room, inpatient service and intensive care patients, respectively. sLRP1 levels rise as severity of Covid19 increases (p= 0.022) (Figure 1). Other biomarkers of inflammation such as CRP display similar trends (Figure 2). Median hsCRP levels are 8.2, 10.2 and 16.4 mg/L for emergency room, service and intensive care patients respectively (p&lt;0.001). Conclusions: Previous studies indicate that LRP1 can be a defense mechanism in acute viral infections. Eliminating LRP1 by siRNA knockdown increases intracellular cholesterol and the infectious virus yield. LRP1 displays a bidirectional course in Covid19. Low sLRP1 can be a risk factor for Covid19. On the other hand, sLRP1 levels increase with disease severity as a defense response to infection. This work was supported by the Research Fund of Istanbul Medeniyet University (project number 1358).
Cells and material-based strategies for regenerative endodontics
Authors: Zain Siddiqui, Amanda M. Acevedo-Jake, Alexandra Griffith, Nurten Kadincesme, Kinga Dabek, Dana Hindi, Ka Kyung Kim, Yoshifumi Kobayashi, Emi Shimizu, Vivek Kumar
Journal: Bioactive Materials (2021)

<p class = "Abstract" style = "margin: 0 cm; line-height: 32px; font-size: 12 pt; font-family: "Times New Roman", serif; color: rgb(0, 0, 0); "><span lang = "EN-US">The carious process leads to inflammation of pulp tissue. Current care options include root canal treatment or apexification. These procedures, however, result in the loss of tooth vitality, sensitivity, and healing. Pulp capping and dental pulp regeneration are continually evolving techniques to regenerate pulp tissue, avoiding necrosis and loss of vitality. Many studies have successfully employed stem/progenitor cell populations, revascularization approaches, scaffolds or material-based strategies for pulp regeneration. Here we outline advantages and disadvantages of different methods and techniques which are currently being used in the field of regenerative endodontics. We also summarize recent findings on efficacious peptide-based materials which target the dental niche.<o:p></o:p></span> .
Abstract 11455: Does Caregiver Burden Change from Before to 24 Months After Surgery: Findings from the Sustaining Quality of Life of the Aged: Heart Transplant or Mechanical Support ( <i>Sustain-it</i> ) Study
Authors: Tingqing Wu, Adin-cristian Andrei, Abigail S Baldridge, Anna Warzecha, Michael Petty, Andrew Kao, John Spertus, eileen hsich, Mary Amanda Dew, Duc Pham, Shane LaRue, William Cotts, Salpy Pamboukian, Francis D Pagani, Brent Lampert, Maryl R Johnson, Justin Hartupee, Koji Takeda, Melana Yuzefpolskaya, Scott Silvestry, James Kirklin, Clyde Yancy, Kathleen L Grady
Journal: Circulation (2021)

Purpose: Caregivers (CGs) provide essential support to older (60-80 years) patients with advanced heart failure (HF), yet caregiving may be burdensome. Understanding the caregivers time spent and difficulty in caring for patients may inform CG support needs before and after cardiac surgery. We compared CG burden before and 24 months after heart transplantation (HT), with or without baseline mechanical circulatory support (MCS), and long-term MCS as destination therapy (DT). Methods: Between 10/1/15-12/31/18, we enrolled 301 CGs of HF patients from 13 U.S. hospitals: 193 awaiting HT (92 with and 101 without MCS), and 108 scheduled for long-term MCS. At baseline (pre-surgery) and 24 months post-surgery, CGs completed the Oberst Caregiving Burden Scale (OCBS), which has 15 items with 2 subscales: (1) time: range=1-5, higher score=more time spent on task and (2) difficulty: range=1-5, higher score=higher task difficulty. Statistical analyses included t-tests and baseline-adjusted linear regression models. Results: CGs’ average age was 60.9±10 years, 83% were spouses, 85% female, and 85% white. Across all groups and both time points, time spent on caregiving tasks was moderate and task difficulty was rated low. Time spent on caregiving decreased significantly from baseline to 24-months for all groups (p-value &lt;0.05 for all; Figure 1A) but task difficulty did not (Figure 1B). At 24-months, mean OCBS time and difficulty scores were significantly higher among CGs of DT patients compared with CGs of HT MCS and HT non-MCS patients. Conclusions: CG time on tasks decreased from baseline to 24-months post-surgery in all groups, and both time and difficulty scores were persistently higher for CGs of DT patients. These results may inform identification of support options to reduce time and difficulty of CG tasks, particularly for those who care for destination therapy HF patients.
Abstract 10358: Incidence of Transesophageal Echocardiography-Related Esophageal Mucosal Injury in Patients with Pulmonary Vein Isolation as a Treatment for Atrial Fibrillation
Authors: Ayumi Omuro, Yasuaki Wada, yasuhiro yoshiga, Shinichi Okuda, Nobuaki Tanaka, Masafumi Yano
Journal: Circulation (2021)

Introduction: Transesophageal echocardiography (TEE) is the gold standard modality for detecting a thrombus in the left atrium (LA) and the left atrial appendage (LAA) prior to pulmonary vein isolation (PVI) for the treatment of atrial fibrillation. Although TEE is has a good safety profile, it was recently reported that TEE preceding PVI can cause esophageal mucosal injury (EMI). However, the detailed data and mechanism of EMI by TEE remain to be elucidated. Herein, we investigated the incidence and risk factors of TEE-related EMI in patients who underwent PVI for AF. Methods: This study included 262 consecutive patients who underwent PVI with preoperative TEE using a 3D TEE probe and postoperative esophagogastroduodenoscopy. The cause of EMI was classified by an experienced gastroenterologist. Results: TEE-related EMI was found in 16 (6.1%) patients, whereas PVI-related EMI was found in 5 (1.9%) patients. Only one patient with TEE-related EMI experienced mild chest discomfort. In the multivariate analysis, advanced age was an independent risk factor for TEE-related EMI (odds ratio, 1.08 per 1-year increment; 95% confidence interval, 1.01-1.16; p = 0.0274). Conclusions: The incidence of TEE-related EMI, for which advanced age could be a significant risk factor, using a 3D TEE probe was relatively high in patients who underwent PVI. This study suggests that attention should be paid to the indications of TEE before performing PVI, especially in elderly patients, and other modalities for ruling out LA and LAA thrombus should also be considered.
Abstract 13861: Cardiac Predictors of Outcomes in Patients With Pulmonary Arterial Hypertension
Authors: Habib Layoun, Nicholas Kassis, Amit Goyal, Tiffany Dong, Anas Saad, Gustavo A Heresi, Adriano Tonelli, Samir R Kapadia, Serge C Harb
Journal: Circulation (2021)

Introduction: Pulmonary arterial hypertension (PAH) has significant anatomical, functional, and hemodynamic effects on the right heart. Yet, the prognostic value of these changes remains unclear. Methods: From the Cleveland Clinic Pulmonary Hypertension Registry, we included patients diagnosed with PAH between 2007-2013 who had right heart cath (RHC), transthoracic echocardiography (TTE), and cardiac computed tomography (CCT) within six months of each other. Right-sided ventricular and valvular anatomy and function were thoroughly assessed with CCT and TTE, while hemodynamics were determined by RHC. The primary outcome was a composite of all-cause mortality and hospitalization for PAH. The mean follow-up was 45 (+/- 42.4) months. Results: A total of 88 patients were included (mean age 55, 79% female). Among CCT, TTE, and RHC variables, RV diastolic pressure was the sole predictor of the primary outcome on multivariable analysis (HR 2.43, p=0.001) (Figure 1). When considering each outcome separately, central venous pressure and RV diastolic pressure were both predictive of death (HR 2.27, p=0.045 and 2.18, p=0.03 respectively), whereas RV diastolic pressure and pulmonary arterial mean pressure were predictors of hospitalization (HR 2.18, p=0.038 and 2.19, p=0.035 respectively) (Table 1). Tricuspid annular anatomy by CCT, and tricuspid regurgitation and RV size and function by TTE were not significantly associated with clinical outcomes. Conclusions: Right heart hemodynamics predict clinical outcomes in patients with PAH, while anatomic and functional characteristics do not.
TAMI-54. SEXUAL DIMORPHISM IN IRON ACQUISITION IN GLIOBLASTOMA
Authors: Bhavyata Pandya, Becky Slagle Webb, Brad Zacharia, Justin Lathia, Joshua Rubin, Michael Berens, Jill Barnholtz-Sloan
Journal: Neuro-Oncology (2021)

Abstract Sexual dimorphism in incidence and the clinical outcomes of Glioblastoma (GBM) has been reported, however, our knowledge of contributing biological mechanisms is limited. Iron acquisition is key to robust tumor growth. Upregulation of Transferrin (TF, iron transport protein)/Transferrin receptor (TFR) is critical for found in multiple different cancers, specifically, we have identified H-ferritin (FTH1) as a contributor to iron transport and protection in cancer stem cells. To interrogate brain tumor iron uptake mechanisms,we performed binding studies on homogenized samples of human male and female GBM tissue samples using 125I labeled TF and FTH1. Tumors from males had a ̴ 3.8-fold increased binding of both proteins compared to tumors from females. We interrogated iron uptake in a syngeneic orthotopic mouse model (GL261 cells) using male and female mice. After the tumors were established, radioactive 125I labeled TF and FTH1 proteins were injected retro-orbitally in the mice. After 24 hours, tumors wereremoved, and analyzed for TF and FTH1 uptake. Male tumors showed an increased uptake, of ̴ 3.2-fold, as compared to female tumors. There was no significant difference in TF uptake between male and female tumors nor between tumor and matched non-tumor brain tissue. We next queried role of FTH1 in the context of sexual dimorphism in GBM in a FTH1+/- mouse strain developed in our laboratory. Survival was monitored in the mice which were injected with GL261 cells at 3 months. Male mice that had reduced expression of FTH1 had poorer survival as compared to the male wild type controls whereas wild type and FTH+/- females had no major differences in survival outcomes. In summary, this study demonstrates sexual dimorphism in iron acquisition in GBM and animal models further suggesting a pathophysiological role of iron metabolism in GBM development and its possible role in prognosis.